Eli Lilly & Co earnings were $13.8B for the trailing 12 months ending Jun 30, 2025, with 88.3% growth year over year. The latest LLY earnings report on Jun 30, 2025 announced Q2 2025 earnings of $5.7B, up 105.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, LLY reported annual earnings of $10.6B, with 102.1% growth.
LLY past earnings growth
How has LLY's earnings growth performed historically?
On LLY's earnings call on Invalid Date, Eli Lilly & Co (NYSE: LLY) reported Q2 2025 earnings per share (EPS) of $6.30, up 91.49% year over year. Total LLY earnings for the quarter were $5.66 billion. In the same quarter last year, Eli Lilly & Co's earnings per share (EPS) was $3.29.
As of the last Eli Lilly & Co earnings report, Eli Lilly & Co is currently profitable. Eli Lilly & Co's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $13.80 billion, a 87.95% increase year over year.
What was LLY's earnings growth in the past year?
As of Eli Lilly & Co's earnings date in Invalid Date, Eli Lilly & Co's earnings has grown 88.34% year over year. This is 37.91 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 50.44%. LLY earnings in the past year totalled $13.80 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.